Phase II clinical trials for Waldenstrom’s macroglobulinemia

Bibliography

• RGOwen, SPTreon, AAl-Katib, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s macroglobulinemia. Semin Oncol 2003;30(2):110-15
   PubMed Web of Science ®Google Scholar
• JWaldenström. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia – a new syndrome? Acta Med Scand 1944;117(3-4):216-47
   Google Scholar
• MAGertz. Waldenstrom macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013;88(8):703-11
   Google Scholar
• JSekhar, KSanfilippo, QZhang, et al. Waldenstrom macroglobulinemia: a surveillance, epidemiology, and end results database review from 1988 to 2005. Leuk Lymphoma 2012;53(8):1625-6
   PubMed Web of Science ®Google Scholar
• HLeblebjian, AAgarwal, IGhobrial. Novel treatment options for waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013;13(Suppl 2):S310-16
   Google Scholar
• PMorel, ADuhamel, PGobbi, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009;113(18):4163-70
   PubMed Web of Science ®Google Scholar
• JJCastillo, AJOlszewski, AMCronin, et al. Survival trends in Waldenstrom macroglobulinemia: an analysis of the surveillance, epidemiology and end results database. Blood 2014;123(25):3999-4000
   PubMed Web of Science ®Google Scholar
• SYKristinsson, SEloranta, PWDickman, et al. Patterns of survival in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol 2013;88(1):60-5
   PubMed Web of Science ®Google Scholar
• MHensel, JBrust, CPloger, et al. Excellent long-term survival of 170 patients with Waldenstrom’s macroglobulinemia treated in private oncology practices and a university hospital. Ann Hematol 2012;91(12):1923-8
   PubMed Web of Science ®Google Scholar
• EKastritis, MCKyrtsonis, EHatjiharissi, et al. No significant improvement in the outcome of patients with Waldenstrom’s macroglobulinemia treated over the last 25 years. Am J Hematol 2011;86(6):479-83
   Google Scholar
• SPTreon, YCao, LXu, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 2014;123(18):2791-6
   PubMed Web of Science ®Google Scholar
• ZRHunter, LXu, GYang, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2014;123(11):1637-46
   PubMed Web of Science ®Google Scholar
• SPTreon, LXu, GYang, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 2012;367(9):826-33
   PubMed Web of Science ®Google Scholar
• YCao, ZRHunter, XLiu, et al. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88 -directed survival signalling in Waldenstrom macroglobulinaemia cells. Br J Haematol 2015;168(5):701-7
   PubMed Web of Science ®Google Scholar
• VNNgo, RMYoung, RSchmitz, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470(7332):115-19
   PubMed Web of Science ®Google Scholar
• EBraggio, JJKeats, XLeleu, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom’s macroglobulinemia. Cancer Res 2009;69(8):3579-88
   PubMed Web of Science ®Google Scholar
• CRabascio, DLaszlo, GAndreola, et al. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenstrom’s Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2’-deoxyadenosine (2-CdA) and Rituximab. Leuk Res 2010;34(4):454-7
   PubMed Web of Science ®Google Scholar
• LShivakumar, SAnsell. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies. Clin Lymphoma Myeloma 2006;7(2):106-8
   PubMedGoogle Scholar
• RGOwen, RAKyle, MJStone, et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 2013;160(2):171-6
   PubMed Web of Science ®Google Scholar
• LSouchet-Compain, SChoquet, VLeblond, SNguyen. Current and future therapeutic approach for Waldenstrom’s macroglobulinemia. Immunotherapy 2014;6(3):333-48
   Google Scholar
• MADimopoulos, MRoussou, EKastritis, et al. Primary Treatment of Waldenstrom’s Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): final Analysis of a Phase II Study. Blood 2012;120(21):438
   Web of Science ®Google Scholar
• ISahin, HLeblebjian, SPTreon, IMGhobrial. Waldenstrom macroglobulinemia: from biology to treatment. Expert Rev Hematol 2014;7(1):157-68
   PubMed Web of Science ®Google Scholar
• IVGupta, RCJewell. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Ann N Y Acad Sci 2012;1263:43-56
   PubMed Web of Science ®Google Scholar
• RRFurman, HEradat, CGDiRienzo, et al. A Phase II trial of ofatumumab in subjects with Waldenstrom’s macroglobulinemia. Blood 2011;118(21):1581-1
   Google Scholar
• SPTreon, JDSoumerai, ZRHunter, et al. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood 2011;118(2):276-81
   PubMed Web of Science ®Google Scholar
• SMHoy. Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia. Drugs 2015;75(3):285-96
   Google Scholar
• MADimopoulos, ETerpos, EKastritis. Proteasome inhibitor therapy for Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013;13(2):235-7
   Google Scholar
• SPTreon, ZRHunter, JMatous, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom’s macroglobulinemia: results of WMCTG trial 03-248. Clin Cancer Res 2007;13(11):3320-5
   PubMed Web of Science ®Google Scholar
• SPTreon, LIoakimidis, JDSoumerai, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009;27(23):3830-5
   PubMed Web of Science ®Google Scholar
• CIChen, CTKouroukis, DWhite, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(12):1570-5
   PubMed Web of Science ®Google Scholar
• IMGhobrial, WXie, SPadmanabhan, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia. Am J Hematol 2010;85(9):670-4
   PubMed Web of Science ®Google Scholar
• IMGhobrial, FHong, SPadmanabhan, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28(8):1422-8
   PubMed Web of Science ®Google Scholar
• MADimopoulos, RGarcia-Sanz, MGavriatopoulou, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood 2013;122(19):3276-82
   PubMed Web of Science ®Google Scholar
• AAgathocleous, ARohatiner, SRule, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Br J Haematol 2010;151(4):346-53
   PubMed Web of Science ®Google Scholar
• ACRosenthal, ACDueck, KGano, et al. A Phase II clinical trial of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBor-D) in relapsed low grade and mantle cell lymphoma. Blood 2014;124:4410 (abstract)
   Google Scholar
• HWang, FGuan, DChen, et al. An analysis of the safety profile of proteasome inhibitors for treating various cancers. Expert Opin Drug Saf 2014;13(8):1043-54
   PubMed Web of Science ®Google Scholar
• SPTreon, CKTripsas, KMeid, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom’s macroglobulinemia. Blood 2014;124(4):503-10
   PubMed Web of Science ®Google Scholar
• DSSiegel, JLKaufman, NSRaje, et al. Updated results from a multicenter, open-label, dose-escalation phase 1b/2 study of single-agent oprozomib in patients with Waldenström macroglobulinemia (WM). Blood 2014;124:1715 (abstract)
   Google Scholar
• SKThomas, AGMeledez, LFeng, et al. Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) Waldenström’s macroglobulinemia (WM). J Clin Oncol 2014;32:5 (Suppl)
   Google Scholar
• MColeman, JLeonard, LLyons, et al. Treatment of Waldenstrom’s macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol 2003;30(2):270-4
   PubMed Web of Science ®Google Scholar
• MADimopoulos, CTsatalas, AZomas, et al. Treatment of Waldenstrom’s macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003;30(2):265-9
   PubMed Web of Science ®Google Scholar
• SPTreon, JDSoumerai, ARBranagan, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112(12):4452-7
   PubMed Web of Science ®Google Scholar
• SPTreon, JDSoumerai, ARBranagan, et al. Lenalidomide and rituximab in Waldenstrom’s macroglobulinemia. Clin Cancer Res 2009;15(1):355-60
   PubMed Web of Science ®Google Scholar
• ACRosenthal, ACDueck, KGano, et al. A phase 2 study of lenalidomide, rituximab, cyclophosphamide and dexamethasone (LR-CD) for untreated low grade non-hodgkin lymphoma requiring therapy: Waldenström’s macroglobulinemia cohort results. Blood 2013;122:4352 (abstract)
   Google Scholar
• XLeleu, SLegouill, CLouni, et al. Lenalidomide is safe and active im Waldenstrom Macroglobulinemia (WM). Blood 2014;124:4478 (abstract)
   Google Scholar
• AYounes, NSamad. Utility of mTOR inhibition in hematologic malignancies. Oncologist 2011;16(6):730-41
   PubMed Web of Science ®Google Scholar
• IMGhobrial, MGertz, BLaplant, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28(8):1408-14
   PubMed Web of Science ®Google Scholar
• IMGhobrial, TEWitzig, MGertz, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol 2014;89(3):237-42
   PubMed Web of Science ®Google Scholar
• IMGhobrial, ARoccaro, FHong, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom’s macroglobulinemia. Clin Cancer Res 2010;16(3):1033-41
   PubMed Web of Science ®Google Scholar
• YBChen, ASLaCasce. Enzastaurin. Expert Opin Investig Drugs 2008;17(6):939-44
   PubMed Web of Science ®Google Scholar
• IMGhobrial, PMoreau, BHarris, et al. A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. Clin Cancer Res 2012;18(18):5043-50
   PubMed Web of Science ®Google Scholar
• AKGopal, BSKahl, Sde Vos, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370(11):1008-18
   PubMed Web of Science ®Google Scholar
• AMarkham. Idelalisib: first global approval. Drugs 2014;74(14):1701-7
   PubMed Web of Science ®Google Scholar
• AKhot, MDickinson, HMPrince. Panobinostat in lymphoid and myeloid malignancies. Expert Opin Investig Drugs 2013;22(9):1211-23
   PubMed Web of Science ®Google Scholar
• JHrabeta, MStiborova, VAdam, et al. Histone deacetylase inhibitors in cancer therapy. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014;158(2):161-9
   Google Scholar
• IMGhobrial, FCampigotto, TJMurphy, et al. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood 2013;121(8):1296-303
   PubMed Web of Science ®Google Scholar
• EKastritis, ETerpos, MADimopoulos. Emerging drugs for Waldenstrom’s macroglobulinemia. Expert Opin Emerg Drugs 2011;16(1):45-57
   PubMed Web of Science ®Google Scholar
• SPTreon, CHanzis, CTripsas, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11(1):133-5
   PubMed Web of Science ®Google Scholar
• MJRummel, NNiederle, GMaschmeyer, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381(9873):1203-10
   PubMed Web of Science ®Google Scholar
• NJHorwood, AMUrbaniak, LDanks. Tec family kinases in inflammation and disease. Int Rev Immunol 2012;31(2):87-103
   PubMed Web of Science ®Google Scholar
• FCameron, MSanford. Ibrutinib: first global approval. Drugs 2014;74(2):263-71
   PubMed Web of Science ®Google Scholar
• SPTreon, GYang, YCao, et al. A prospective multicenter study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom’s Macroglobulinemia. Proc Am Soc Hematol Blood 2013;122:251 (abstract)
   Google Scholar
• JJCastillo, SKanan, KMeid, et al. Incidence and survival outcomes of secondary malignancies among survivors of Waldenstrom macroglobulinemia. Blood 2014;124:855 (abstract)
   Google Scholar